DDInter864 DDInter1376
Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that need to be replaced every 52 weeks.[L41700,L41715,L41755] Initially, histrelin implants were developed to reduce testosterone to castration levels in patients with advanced prostate cancer. The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Histrelin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Histrelin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Risperidone
Histrelin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Histrelin {u} may lead to a major life threatening interaction when taken with {v} Arsenic trioxide
Histrelin {u} may lead to a major life threatening interaction when taken with {v} Lefamulin
Histrelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Risperidone
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Histrelin may lead to a major life threatening interaction when taken with Arsenic trioxide
Histrelin may lead to a major life threatening interaction when taken with Lefamulin